Heterozygous
familial hypercholesterolemia (HeFH) is an inherited genetic disorder that affects the body’s
ability to control cholesterol. It is characterized by very high LDL (low
density lipoprotein) cholesterol (above 190 for adults or above 160 for children)
and family history of high cholesterol, heart disease or stroke.
Access
More About This Research at:
A very high
level of LDL from birth leads to a twenty-fold increase in the risk of
premature cardiovascular diseases. About 1 in 250 people around the world have
HeFH and only about 10% of people with this medical condition have been
diagnosed.
Request
to Get the Sample Pages at:
Diagnosis is
important because there are several early aggressive treatments available which
can lower the risk for heart diseases or stroke.
The drug
candidates of HeFH pipeline include, but not limited to, GEM-201 and
anacetrapib. Some of the other companies having drugs in the HeFH pipeline
includes Gemphire Therapeutics Inc. and Merck & Co. Inc.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment